Literature DB >> 33093159

Determinants of Guideline-Discordant Breast Cancer Care.

Jean A McDougall1,2, Linda S Cook3,2, Mei-Tzu C Tang4, Hannah M Linden5,6, Beti Thompson4,7, Christopher I Li4,8.   

Abstract

BACKGROUND: Evidence-based breast cancer treatment guidelines recommend the most appropriate course of therapy based on tumor characteristics and extent of disease. Evaluating the multilevel factors associated with guideline discordance is critical to identifying strategies to eliminate breast cancer survival disparities.
METHODS: We identified females diagnosed with a first primary, stage I-III breast cancer between the ages of 20-69 years of age from the population-based Seattle-Puget Sound Surveillance, Epidemiology, and End Results registry. Participants completed a survey about social support, utilization of patient support services, hypothesized barriers to care, and initiation of breast cancer treatment. We used logistic regression to estimate odds ratios and 95% confidence intervals (CI).
RESULTS: Among 1,390 participants, 10% reported guideline-discordant care. In analyses adjusted for patient-level sociodemographic factors, individuals who did not have someone to go with them to appointments or drive them home (OR 1.96; 95% CI, 1.09-3.59) and those who had problems talking to their doctors or their staff (OR 2.03; 95% CI, 1.13-3.64) were more likely to be guideline discordant than those with social support or without such problems, respectively. Use of patient support services was associated with a 43% lower odds of guideline discordance (OR 0.57; 95% CI, 0.36-0.88).
CONCLUSIONS: Although guideline discordance in this cohort of early-stage breast cancer survivors diagnosed <70 years of age was low, instrumental social support, patient support services, and communication with doctors and their staff emerged as potential multilevel intervention targets for improving breast cancer care delivery. IMPACT: This study supports extending the reach of interventions designed to improve guideline concordance. ©2020 American Association for Cancer Research.

Entities:  

Mesh:

Year:  2020        PMID: 33093159      PMCID: PMC7855615          DOI: 10.1158/1055-9965.EPI-20-0985

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.090


  43 in total

1.  Social networks, social support mechanisms, and quality of life after breast cancer diagnosis.

Authors:  Candyce H Kroenke; Marilyn L Kwan; Alfred I Neugut; Isaac J Ergas; Jaime D Wright; Bette J Caan; Dawn Hershman; Lawrence H Kushi
Journal:  Breast Cancer Res Treat       Date:  2013-05-09       Impact factor: 4.872

2.  Multilevel factors affecting quality: examples from the cancer care continuum.

Authors:  Jane Zapka; Stephen H Taplin; Patricia Ganz; Eva Grunfeld; Katherine Sterba
Journal:  J Natl Cancer Inst Monogr       Date:  2012-05

Review 3.  A review of cost communication in oncology: Patient attitude, provider acceptance, and outcome assessment.

Authors:  Ya-Chen Tina Shih; Chun-Ru Chien
Journal:  Cancer       Date:  2016-11-28       Impact factor: 6.860

4.  Social networks, social support, and survival after breast cancer diagnosis.

Authors:  Candyce H Kroenke; Laura D Kubzansky; Eva S Schernhammer; Michelle D Holmes; Ichiro Kawachi
Journal:  J Clin Oncol       Date:  2006-03-01       Impact factor: 44.544

5.  Cancer statistics, 2020.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2020-01-08       Impact factor: 508.702

6.  Relationship between Diabetes and Diabetes Medications and Risk of Different Molecular Subtypes of Breast Cancer.

Authors:  Hongjie Chen; Linda S Cook; Mei-Tzu C Tang; Deirdre A Hill; Charles L Wiggins; Christopher I Li
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2019-08-08       Impact factor: 4.254

7.  Disparities in the Initial Local Treatment of Older Women with Early-Stage Breast Cancer: A Population-Based Study.

Authors:  Traci J LeMasters; Suresh S Madhavan; Usha Sambamoorthi; Ami M Vyas
Journal:  J Womens Health (Larchmt)       Date:  2017-02-07       Impact factor: 2.681

8.  Expanding access to cancer screening and clinical follow-up among the medically underserved.

Authors:  H P Freeman; B J Muth; J F Kerner
Journal:  Cancer Pract       Date:  1995 Jan-Feb

9.  Disparities in Use of Human Epidermal Growth Hormone Receptor 2-Targeted Therapy for Early-Stage Breast Cancer.

Authors:  Katherine Reeder-Hayes; Sharon Peacock Hinton; Ke Meng; Lisa A Carey; Stacie B Dusetzina
Journal:  J Clin Oncol       Date:  2016-04-11       Impact factor: 44.544

10.  Exploring the role of social support and adjuvant endocrine therapy use among breast cancer survivors.

Authors:  Gabriela Toledo; Carol Y Ochoa; Albert J Farias
Journal:  Support Care Cancer       Date:  2019-04-29       Impact factor: 3.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.